Ensysce Biosciences Reports Third Quarter 2026 Financial Results and Business Highlights
Key Highlights
- ➤Cash $29.7 million, up from $4.3 million at December 31, 2025
- ➤Net loss $82.3 million, including $79.9 million non-cash acquisition charge
- ➤Ensysce completed enrollment in final PF614-MPAR-102 study stage
- ➤MHRA requested additional information for CY200 Phase 2a trial application
- ➤Cy Biopharma acquisition added CY200 as Ensysce’s lead CRPS asset
Expert Statements
Lynn Kirkpatrick, Chief Executive Officer of Ensysce
“Ensysce is a fundamentally different company today than it was at the start of the year”
Lynn Kirkpatrick, Chief Executive Officer of Ensysce
“With CY200, we now lead with a potentially first-in-class approach to CRPS, a devastating condition for which there is currently no FDA-approved therapy.”
Lynn Kirkpatrick, Chief Executive Officer of Ensysce
“At the same time, completing enrollment in PF614-MPAR-102 brings us closer to the clinical evidence needed to advance what we believe is the first opioid engineered with built-in overdose protection.”
Lynn Kirkpatrick, Chief Executive Officer of Ensysce
“With a strengthened balance sheet and two differentiated pain programs, our focus now is on initiating the CY200 Phase 2a study and delivering on the milestones ahead.”
James Morrison, President of Ensysce
“Our priority since the acquisition has been to advance CY200 efficiently, and submitting the CYBIO 001 protocol to the MHRA in September was a significant first step”
James Morrison, President of Ensysce
“Patients with CRPS have very few treatment options.”
James Morrison, President of Ensysce
“Our focus now is on preparing our sites and clinical team so we are ready to commence enrollment as soon as practicable once we receive regulatory clearance in the UK.”
SAN DIEGO, CA / ACCESS Newswire / November 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing innovative neuroplastogenic therapies beyond mood disorders, with an initial focus on Complex Regional Pain Syndrome ("CRPS"), today reported financial and operational results for the third quarter ended September 30, 2026.
The third quarter of 2026 was a transformational period for Ensysce. In August, the Company completed the acquisition of Cy Biopharma, Inc. ("Cy Biopharma"), adding CY200, a clinical-stage neuroplastogenic candidate for CRPS whose active ingredient has received FDA Orphan Drug Designation, as its lead pipeline asset, and in September submitted the protocol for a Phase 2a study of CY200 to the UK Medicines and Healthcare products Regulatory Agency (MHRA). Ensysce also completed enrollment in the final stage of the PF614-MPAR-102 study of its Breakthrough Therapy-designated, overdose-protected opioid. The Company ended the quarter with $29.7 million in cash and cash equivalents.
Get started
Create a free account to read the full story.